Suppr超能文献

聚合酶链式反应(PCR)之外的技术:用于传染病诊断的替代靶标扩增技术,第一部分

Life beyond PCR: alternative target amplification technologies for the diagnosis of infectious diseases, part I.

作者信息

Ginocchio Christine C

机构信息

Microbiology, Virology, and Molecular Diagnostics, North Shore - Long Island Jewish Health System Laboratories, Lake Success, NY, USA.

出版信息

Clin Microbiol Newsl. 2004 Aug 15;26(16):121-128. doi: 10.1016/j.clinmicnews.2004.08.001. Epub 2004 Aug 11.

Abstract

Non-PCR-based target amplification technologies, including transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), and strand displacement amplification (SDA), are currently the basis for a broad range of clinical infectious-disease molecular diagnostics. These amplification technologies are very sensitive and specific and can be used in combination with traditional end-point or "real-time" detection formats. For several nucleic acid targets, TMA, NASBA, and SDA have certain advantages over PCR-based applications. This two-part article will review the molecular basis of each technology and how the technology has been applied to clinical diagnostic systems. The articles will describe the current testing platforms available, U.S. Food and Drug Administration (FDA)- and non-FDA-approved assays, and availability of analyte-specific reagents. In addition, an open-platform system is described that utilizes standardized reagents and methods and allows the user to develop in-house protocols. Finally, applications for the future are discussed.

摘要

基于非聚合酶链反应(PCR)的靶标扩增技术,包括转录介导扩增(TMA)、基于核酸序列的扩增(NASBA)和链置换扩增(SDA),目前是广泛的临床传染病分子诊断的基础。这些扩增技术非常灵敏且特异,可与传统的终点或“实时”检测形式结合使用。对于几种核酸靶标,TMA、NASBA和SDA相对于基于PCR的应用具有某些优势。这篇分两部分的文章将回顾每种技术的分子基础以及该技术如何应用于临床诊断系统。文章将描述当前可用的检测平台、美国食品药品监督管理局(FDA)批准和未批准的检测方法以及分析物特异性试剂的可用性。此外,还描述了一种开放平台系统,该系统使用标准化试剂和方法,并允许用户开发内部方案。最后,讨论了未来的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ca0/7124326/68a0188d74a9/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验